TABLE 1.
Baseline Characteristics
| Variable | Cohort 1 (N = 52) | Treatment-Naïve (n = 35) | Previously Treated (n = 17) |
|---|---|---|---|
| Age, years | |||
| Mean (standard deviation) | 71.3 (8.3) | 71.9 (9.0) | 70.0 (6.5) |
| Median (min, max) | 71.0 (51.0, 90.0) | 71.0 (53.0, 90.0) | 70.0 (57.0, 80.0) |
| Sex, No. (%) | |||
| Male | 29 (55.8) | 18 (51.4) | 11 (64.7) |
| Female | 23 (44.2) | 17 (48.6) | 6 (35.3) |
| ECOG PS, No. (%) | |||
| 0 | 5 (9.6%) | 5 (14.3) | 0 (0.0) |
| 1 | 47 (90.4%) | 30 (85.7) | 17 (100.0) |
| Smoking, No. (%)a | |||
| Current | 3 (5.8) | 2 (5.9) | 1 (5.9) |
| Former | 16 (30.8) | 10 (29.4) | 6 (35.3) |
| Never | 32 (61.5) | 22 (64.7) | 10 (58.8) |
| Histologic subtype, No. (%) | |||
| Adenocarcinoma | 47 (90.4) | 31 (88.6) | 16 (94.1) |
| Squamous carcinoma | 1 (1.9) | 1 (2.9) | 0 (0.0) |
| Large cell lung cancer | 1 (1.9) | 0 (0.0) | 1 (5.9) |
| NSCLC, not otherwise specified | 3 (5.8) | 3 (8.6) | 0 (0.0) |
| Disease stage, No. (%) | |||
| IIIB | 5 (9.6) | 5 (14.3) | 0 (0.0) |
| IIIC | 4 (7.7) | 3 (8.6) | 1 (5.9) |
| IV | 43 (82.7) | 27 (77.1) | 16 (94.1) |
| Previous systematic antitumor treatment, No. (%) | |||
| Chemotherapy | — | 16 (94.1) | |
| Target therapy | — | 3 (17.6) | |
| Immunotherapy | — | 5 (29.4) |
Abbreviations: ECOG PS, Eastern Cooperative Oncology Group performance status; NSCLC, non–small cell lung cancer.
a
S04001 missing smoking history information.